Taking place at the 15th congress of the European Crohn’s and Colitis Organisation (ECCO) in the beautiful Austrian capital of Vienna, the AbbVie-sponsored symposium “The Illusion of Remission” garnered discussion on the use of corticosteroids to treat inflammatory bowel disease (IBD) and the important considerations that need to be made alongside the decision by physicians to prescribe.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.